Clinical Trials Sponsored by Research Center, LLC

Total 15432 results

Janssen Research & Development, LLC

Completed

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Multiple Myeloma

United States, Spain, Canada
Janssen Research & Development, LLC

Completed

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

United States, Australia, France, United Kingdom, Belgium, Germany, Spain, Canada, Netherlands, Greece, Sweden
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease

Multicentric Castleman's Disease

United States, Canada, France, United Kingdom, China, Germany, Taiwan, Spain, Israel, Korea, Republic of, Singapore, Brazil, Belgium, New Zealand, Norway, Egypt, Hong Kong
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir

Renal Insufficiency

United States
Janssen Research & Development, LLC

Completed

Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma

Multiple Myeloma

United States, Netherlands, Sweden, Denmark
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

Multicentric Castleman's Disease

United States, Canada, France, United Kingdom, China, Germany, Taiwan, Spain, Belgium, Israel, India, Korea, Republic of, Netherlands, Singapore, Brazil, Russian Federation, New Zealand, Hungary, Norway, Australia, Egypt, Hong Kong, Malaysi...
Janssen Research & Development, LLC

Completed

A Study of Golimumab in Participants With Active Psoriatic Arthritis

Arthritis, Psoriatic

Poland, Ukraine, United States, Germany, Belarus, Spain, Romania, Russian Federation, Hungary, Lithuania, Australia, Canada
Janssen Research & Development, LLC

Withdrawn

Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Withdrawn

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

Germany
Janssen Research & Development, LLC

Withdrawn

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

Healthy

United States
Janssen Research & Development, LLC

Completed

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Prostate Cancer

Japan
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Subjects

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

Psoriasis

United States
Janssen Research & Development, LLC

Completed

Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007

Pain | Osteoarthritis

United States, Australia, Poland, Korea, Republic of, Canada, Germany, Hungary, Spain, Czechia, Sweden, United Kingdom
Janssen Research & Development, LLC

Completed

Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States

Diabetes Mellitus, Type 2
Janssen Research & Development, LLC

Completed

A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration

Age-related Macular Degeneration

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Diabetes Mellitus, Type 2

United States, Ukraine, Argentina, Mexico, Romania, South Africa, Korea, Republic of, Russian Federation, Brazil, Puerto Rico, Hungary, Slovakia, Czechia
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents

Diabetes Mellitus, Type 2
Janssen Research & Development, LLC

Completed

Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects

Healthy

United States
MDbackline, LLC
Alcon Research

Completed

Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%

Cataract

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis

Arthritis, Rheumatoid

Germany, Korea, Republic of, South Africa, Moldova, Republic of
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

Psychotic Disorders | Schizophrenia | Schizophrenic Disorders | Dementia Praecox

United States, Belgium, Poland, Bulgaria, India, Romania, Russian Federation, Ukraine, Korea, Republic of, Estonia, Finland
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Janssen Research & Development, LLC

Withdrawn

A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (TOGETHER)

Prostatic Neoplasms
Janssen Research & Development, LLC

Completed

CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

Diabetes Mellitus, Type 2

United States, Poland, Germany, Israel, Bulgaria, Costa Rica, India, Romania, Ukraine, Finland, Korea, Republic of, Canada, Philippines, Russian Federation, Argentina, Norway, Denmark, Slovakia, Mexico, Puerto Rico
Janssen Research & Development, LLC

Completed

To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma

Healthy

Belgium
Janssen Research & Development, LLC

Withdrawn

A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate

Active Rheumatoid Arthritis; Rheumatoid Arthritis
Janssen Research & Development, LLC

Completed

A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

Neoplasms

United States, Spain, Canada, Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants

Helminth Infections

Ethiopia, Rwanda
Janssen Research & Development, LLC

Completed

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Lymphoma, T-Cell, Cutaneous

France, United Kingdom, Spain, Portugal, United States, Germany
Janssen Research & Development, LLC

Completed

A Study of Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications

Myocardial Infarction | Stroke | Kidney Diseases | Hemorrhage, Gastrointestinal

United States
Janssen Research & Development, LLC

Completed

First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Janssen Research & Development, LLC

Completed

A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics (PARIS)

Psoriatic Arthritis

China, Korea, Republic of, Australia
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation

Influenza A Virus

Belgium
Janssen Research & Development, LLC

Completed

A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma

Asthma

United States, France, United Kingdom, Germany, Israel, Canada
Janssen Research & Development, LLC

Completed

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

Arthritis, Rheumatoid

Poland, Ukraine, Colombia, Bulgaria, United States, Singapore, Russian Federation, Argentina, Hungary, Chile, Czech Republic
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

Schizophrenia

United States, Ukraine, Colombia, Mexico, Malaysia, Romania, Korea, Republic of, Turkey
Janssen Research & Development, LLC

Completed

Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

Schizophrenia

France, United States, China, Spain, Argentina, Mexico, Portugal, Bulgaria, Germany, Poland, Russian Federation, Ukraine, Japan, Greece, Taiwan, Korea, Republic of, Canada, Czech Republic, Brazil, Hungary, Austria, Sweden, Romania, Sl... and more
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants

Healthy

United States

3

Subscribe